Back to top
more

Jounce Therapeutics, Inc. (JNCE)

(Delayed Data from NSDQ)

$5.79 USD

5.79
66,579

+0.42 (7.82%)

Updated May 3, 2019 04:00 PM ET

After-Market: $5.78 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

United Therapeutics (UTHR) Q1 Earnings Beat, Sales Miss

United Therapeutics' (UTHR) first-quarter 2023 earnings beat estimates while sales miss the same. Tyvaso sales continue to drive the company's top line.

Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics

Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics are part of the Zacks Industry Outlook article.

Kinjel Shah headshot

5 Stocks to Buy as the Drug Industry Rebounds in 2023

Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. CPRX, KALV, LRMR, NKTR, JNCE may prove to be good additions to one's portfolio.

Jounce (JNCE) Up 21% on Accepting Concentra's Buyout Offer

Jounce Therapeutics (JNCE) is set to be acquired by Concentra Biosciences, spurning an all-share merger deal with British biotech firm Redx Pharma.

Jounce (JNCE) Up 41% on Buyout Offer From Concentra Biosciences

Jounce Therapeutics (JNCE) receives a proposal from Concentra Biosciences to acquire 100% equity stake in the company.

Gilead (GILD) Gains 21% in a Year: Will the Trend Continue?

Biotech giant Gilead (GILD) gains 21% in the past 12 months as its core HIV business maintains momentum despite volatility.

Gilead's (GILD) Application for Trodelvy Gets EMA Validation

Gilead Sciences (GILD) gets EMA validation for its application for breast cancer drug Trodelvy in the European Union.

Gilead (GILD) To Get Full Rights for Jounce's Immunotherapy

Gilead Sciences (GILD) is set to buy the remaining rights to the potential first-in-class immunotherapy GS-181 from Jounce Therapeutics.

Biotech Stock Roundup: BMY's Study Update, INCY's Drug Label Expansion, MRNA News

Regulatory updates from Bristol Myers (BMY) and Incyte (INCY) are a few key highlights from the biotech sector during the past week.

Jounce (JNCE) SELECT Study Fails to Meet Goal, Stock Down

Jounce Therapeutics (JNCE) declines as its mid-stage study, SELECT, evaluating vopratelimab in lung cancer patients, fails to meet the primary endpoint.

Jounce Therapeutics, Inc. (JNCE) Reports Q4 Loss, Lags Revenue Estimates

Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of -156.52% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Misses Revenue Estimates

BioCryst (BCRX) delivered earnings and revenue surprises of -29.03% and 2.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Jounce Therapeutics, Inc. (JNCE) to Report a Decline in Earnings: What to Look Out for

Jounce Therapeutics, Inc. (JNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Organogenesis (ORGO) Stock Jumps 7.4%: Will It Continue to Soar?

Organogenesis (ORGO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Jounce Therapeutics, Inc. (JNCE) Reports Q3 Loss, Lags Revenue Estimates

Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of -47.50% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Jounce Therapeutics, Inc. (JNCE) Reports Q2 Loss, Tops Revenue Estimates

Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of 78.95% and 167.71%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Gilead (GILD) Gains 19% YTD: What to Expect in The Second Half?

Gilead (GILD) maintains momentum in the year so far on the back of Veklury for the treatment of COVID-19 and the same is expected to continue in the second half.

Jounce Therapeutics, Inc. (JNCE) Reports Q1 Loss, Misses Revenue Estimates

Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of -56.76% and -97.53%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Are Options Traders Betting on a Big Move in Jounce Therapeutics (JNCE) Stock?

Investors need to pay close attention to Jounce Therapeutics (JNCE) stock based on the movements in the options market lately.

Williams-Sonoma, Tanger Factory Outlet, Gilead Sciences, Immunomedics and Jounce Therapeutics highlighted as Zacks Bull and Bear of the Day

Williams-Sonoma, Tanger Factory Outlet, Gilead Sciences, Immunomedics and Jounce Therapeutics highlighted as Zacks Bull and Bear of the Day

Gilead's Oncology Drug Gets Breakthrough Therapy Designation

Gilead's (GILD) magrolimab obtains Breakthrough Therapy designation in the United States for the treatment of newly-diagnosed myelodysplastic syndrome (MDS).

Gilead to Buy Oncology Company Immunomedics for $21 Billion

Gilead (GILD) looks to fortify its oncology portfolio with the acquisition of Immunomedics and the addition of Trodelvy to its portfolio.

Gilead-HiFiBiO Ink Deal to Develop Antibodies Against Leukemia

Gilead's (GILD) subsidiary, Kite, enters into a two-year research deal with HiFiBiOto develop antibodies against acute myeloid leukemia.

Gilead Inks Deal With Jounce to License an Oncology Candidate

Gilead (GILD) signs a deal with Jounce Therapeutics to exclusively license the latter's monoclonal antibody, JTX-1811.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for February 27th

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for today: